TheraPEG patent highlights benefits of PEGylation technology
This article was originally published in Scrip
Executive Summary
PolyTherics’ European patent for its TheraPEG PEGylation technology (www.scripnews.com, 22 June 2009) is indeed a significant milestone for the company. With allowance of the US TheraPEG patent expected “very soon”, all products incorporating the TheraPEG technology will be protected throughout their development and once they reach the market. This will not only secure commercial freedom for those products but, going forward, it will also generate licensing and royalty revenues for PolyTherics.